ClinicalTrials.gg
CompletedNCT02202161Updated Nov 6, 2017Results posted

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

A Phase 2 interventional study of GSK2330672 and Placebo in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 4 sites in United States. Open to participants aged 30 Years to 64 Years. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
30 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · GlaxoSmithKline.

Enrollment
62nd of 125
70 · median 70
Started
2014
with 3 others
Phase 2
22 of 136
none open now
Registered
126th of 136
by date

Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 62nd largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2014, is one of 22 in phase 2, and was the 126th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline as a file.
02

Study summary

This study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2330672 compared to sitagliptin when administered with metformin for 14 days to subjects with type 2 diabetes mellitus (T2DM). Approximately 72 male and female subjects aged 30-64 years with T2DM and currently taking metformin will be recruited for this study. Eligible subjects will begin a run-in period of 13-15 days to stabilize on metformin 850 milligram (mg) twice a day (BID). Subjects will then be randomized to GSK2330672 10 mg, 20 mg, 30 mg, 90 mg, matching placebo or open-label sitagliptin 50 mg for 14 days BID. Subjects will return for a follow-up visit 7-10 days after discharge.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • pharmacokinetic
  • intestinal bile acid transporter inhibitor
  • metformin
  • sitagliptin
  • GSK2330672
  • pharmacodynamic
04

Who can participate

Ages eligible
30 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 30 and 64 years of age inclusive, at the time of signing the
  • Subjects with a diagnosis of T2DM for at least 3 months prior to screening, taking metformin for at least 4 weeks prior to screening, taking a metformin daily dose of>= 1000 mg and having an Glycosolated (HbA1c) value of 7-11% inclusive at screening. The investigator should make an effort to obtain documentation of medical history or prescription of metformin to substantiate the diagnosis of T2DM
  • Fasting plasma glucose \<280 milligram per deciliter (mg/dl) at screening. A subject with a fasting plasma glucose at Day 1 that is more than 100 mg/dl lower than the screening value must not be randomized
  • All T2DM subjects must meet the label recommendations for metformin and sitagliptin, including: Adequate renal function, as evidenced by an estimated >= 80 milliliter per minute (mL/min) using the modification of diet in renal disease (MDRD) equation or chronic kidney disease epidemiology collaboration (CKD-EPI) formula in the study procedures manual (SPM); No conditions which make hypoxia, dehydration, or sepsis likely; No cardiac disease (including no history of myocardial infarction, stroke, hospitalization for acute coronary syndrome, or heart failure)
  • (BMI) within the range 24 - 40 kilogram per meter square (kg/m\^2) (inclusive)
  • Other than T2DM, subjects should be in good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or physical examination that would introduce additional risk factors or interfere with study procedures or objectives, based on a medical evaluation including medical history, physical examination, vital signs, and laboratory tests
  • A female subject is eligible to participate if she is of non- defined as: Pre-menopausal females with a documented tubal ligation, bilateral oophorectomy, or hysterectomy [for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records]; OR defined as 12 months of spontaneous amenorrhea. In questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 million international units (MlU)/mL and estradiol \< 40 picogram (pg)/mL (\<147 picomol per liter) is confirmatory. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the methods as described by the Investigator/designee, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method
  • Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods as described by the Investigator/designee. This criterion must be followed from the time of the first dose of study medication until the follow-up visit
  • Subjects must be willing to discontinue their usual dose of metformin and take the study dose of 850 mg immediate release formulation metformin BID for the 13-15 day run-in period and the 2-week treatment period
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion criteria

Exclusion Criteria:

  • The use of approved non-metformin anti-diabetic agents within 3 months of the screening visit
  • Hypoglycemia unawareness. T2DM subjects are excluded if, in the opinion of the investigator, they have significant hypoglycemia unawareness (for example, no symptoms of hypoglycemia when the blood glucose level is \<70 mg/dl)
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome). Subjects with a history of cholelithiasis, biliary colic, inflammatory gall bladder disease and/or cholestatic liver disease are excluded, unless this results in curative cholecystectomy 3 months or more before screening and with the approval of the GlaxoSmithKline (GSK) Medical Monitor
  • History of chronic or acute pancreatitis. Approval from the GSK Medical Monitor must be obtained for subjects with a past history of pancreatitis more than 12 months from the start of the Treatment Period (subjects with a history of pancreatitis within 12 months prior to the start of the Treatment Period are excluded). NOTE: Subjects with a lipase value above the (ULN) at screening are excluded. A single repeat assessment is allowed within 3 days of the original test
  • History of Gastrointestinal (GI) disease (e.g., irritable bowel disease, chronic or current diarrhea, inflamed bowel, steatorrhoea/fat malabsorption, celiac disease, symptomatic lactose intolerance, small bowel resection). Subjects with gastroparesis requiring treatment are excluded. Subjects with history of prolapsed or bleeding haemorrhoids within 1 month of screening are excluded unless approved by the GSK Medical Monitor
  • History of autonomic neuropathy
  • History of epilepsy and/or use of anti-convulsants, including but not limited to phenobarbitone, phenytoin, carbamazepine, valproate
  • History of serious, severe, or unstable physical or psychiatric illness including depression, suicidal thoughts, schizophrenia, bipolar disorder, or generalized anxiety disorder. In addition to elicited symptoms and signs, this should include specific questions relating to known psychiatric diagnoses and medications used
  • History of significant cardiovascular disease not covered by the label recommendations for metformin, for example, ventricular tachyarrhythmias, peripheral arterial disease, and pulmonary embolism, within the previous 12 months
  • Uncontrolled hypertension, as evidenced by systolic pressure >160 millimeters of mercury (mmHg) or diastolic pressure >90 mmHg on a single assessment. If systolic pressure >140 mmHg or diastolic pressure >90 mmHg, a single repeat is allowed within 1 hour. Subjects whose blood pressure is well-controlled by taking anti-hypertensive medications (e.g., beta blockers, angiotensin converting enzyme(ACE) inhibitors, angiotensin II receptor antagonists, calcium channel blockers, and thiazide diuretics) are permitted
  • History of untreated pernicious anemia or who have laboratory parameters suggestive of subclinical megaloblastic anemia (e.g., increased mean corpuscular volume [MCV] with low red blood cells [RBC] count and/or [Hb] level).
  • Thyroid disease: Uncorrected Thyroid Dysfunction as Fasting plasma thyroid stimulating hormone (TSH) outside of the normal range, as determined at the screening visit. Subjects on stable thyroid replacement therapy and with TSH in the normal range are eligible if approved by the GSK Medical Monitor. Unevaluated thyroid nodule or goiter at screening
  • History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits
  • History of sensitivity to heparin or heparin-induced thrombocytopenia
  • History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy (including other Dipeptidyl Peptidase-IV [DPP-IV] inhibitors) that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
  • Current or relevant previous significant medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that, in the opinion of the investigator, presents undue risk from the study medication or procedures
  • (ALT)>2xULN and >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • Fasting triglycerides >= 400 mg/dl for subjects without a history of pancreatitis or >250 mg/dl for subjects with a history of pancreatitis. Approval from the GSK Medical Monitor must be obtained for subjects with a past history of pancreatitis more than 12 months from the start of the treatment period (subjects with a history of pancreatitis within 12 months prior to the start of the treatment period are excluded). Subjects taking statins, ezetimibe, or Vytorin are permitted in the study. Subjects taking other lipid therapies, including but not limited to niacin, bile acid sequestrants and/or fibrates are not eligible
  • C-peptide of \<0.8 nanogram (ng)/mL at screening
  • Urine albumin-to-creatinine ratio >0.3 mg albumin/mg creatinine
  • Positive fecal occult blood test at screening or during the run-in period
  • Significant abnormalities, defined as follows: Heart Rate (resting) was \<50 and >100 beats per minute (bpm); PR Interval between \<120 and >220 millisecond (msec); QRS duration between \<70 and >120 msec
  • Based on averaged of triplicate ECGs obtained at least 1 minute apart within approximately 15 minutes: QT duration corrected for heart rate by Fridericia's formula (QTcF) >= 450 msec; OR QTcF >= 480 msec in subjects with right Bundle Branch Block (subjects with left bundle branch block are excluded)
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening
  • A positive test for antibody
  • A positive urine drug screen or alcohol breath test at screening or during the run-in or treatment periods
  • A subject with a positive urine cotinine test result will be excluded from the study unless in the judgment of the investigator the subject will be able to abstain from using tobacco for the duration of the in-clinic treatment period of the study
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
  • Subjects who have participated in a previous study with GSK2330672 are excluded
  • Because of the potential impact on bile acid synthesis and secretion in the liver, use of rifampicin and/or other pregnane X receptor (PXR) inducers, including but not limited to St. John's Wort, is cause for subject exclusion
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    GSK2330672 10 mg

    Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.

    Drug: GSK2330672 · Drug: Metformin

  • Experimental
    GSK2330672 20 mg

    Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.

    Drug: GSK2330672 · Drug: Metformin

  • Experimental
    GSK2330672 30 mg

    Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.

    Drug: GSK2330672 · Drug: Metformin

  • Experimental
    GSK2330672 90 mg

    Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.

    Drug: GSK2330672 · Drug: Metformin

  • Placebo comparator
    GSK2330672-matched placebo

    Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.

    Drug: Placebo · Drug: Metformin

  • Active comparator
    Sitagliptin 50 mg

    Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.

    Drug: Sitagliptin · Drug: Metformin

Interventions

  • GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed

  • DrugPlacebo

    Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed

  • Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days

  • Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour])

    The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value. It was assessed on Baseline, Day 7 and 14. Data for fasting and weighted mean (WM) AUC(0-24 hour) glucose is provided. Statistics for least square mean is provided and participants withdrawing early were excluded. Results were based on an analysis of covariance (ANCOVA) model: change from Baseline = Baseline + treatment.

    Time frame: Baseline (Day -1) and Day 14 (Fasting Pre-dose [within 15 minutes of dose], 30 minutes, 1, 1.5, 2, 4 [pre-lunch], 5.5, 10 [pre-dinner], 11.5, 14 [bed time] and 24 hours) and Day 7 (30 minutes, 2, 4 [pre-lunch], 5.5, 10 [pre-dinner], 11.5, and 24 hours)

  2. Number of Participants With Incidence and Nature of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition and alanine aminotransferase (ALT) \>= 3× upper limit of normal (ULN) and total bilirubin \>=2 × ULN (\>35% direct) or ALT \>=3 × ULN and international normalized ratio \>1.5.

    Time frame: Up to 14 days (treatment period)

  3. Number of Participants With Abnormal Hematology With Potential Clinical Concern (PCI)

    Hematology parameters included platelet, red blood cell (RBC) count, mean corpuscular volume (MCV), neutrophils, white blood cell (WBC) count (absolute), mean corpuscular hemoglobin (MCH), lymphocytes, mean corpuscular hemoglobin concentration (MCHC), monocytes, hemoglobin, eosinophils, hematocrit and basophils. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided.

    Time frame: Up to Day 15

  4. Number of Participants With Abnormal Clinical Chemistry With PCI

    Clinical chemistry parameters included blood urea nitrogen (BUN), potassium, aspartate aminotransferase (AST), total bilirubin, direct bilirubin, creatinine, chloride, alanine aminotransferase (ALT), uric acid, fasting glucose, total carbon dioxide, gamma glutamyltransferase (GGT), albumin, sodium, calcium, alkaline phosphatase (ALP), total protein, total carbon dioxide and triglycerides. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided. The normal range (NR) and PCI definition for abnormal parameters are: ALT (NR: 0-44, 0-32, 2-33; PCI: \>=2×upper limit of normal \[ULN\]); AST (NR: 0-40; PCI: \>=2× ULN) and total bilirubin (NR: 0.00-20.52; PCI: \>=1.5× ULN).

    Time frame: Up to Day 15

  5. Number of Participants With Abnormal Urinalysis Data

    Urinalysis included urine occult blood: trace to 3+, glucose: negative to 3+, protein: negative to 2+ and ketones: trace to negative by dipstick and microscopic examination included cast, cellular cast, granular cast, hyaline cast (none seen to 1) and RBC: 0-2, 3-10, 11-30, \>30, WBC: none seen, 0-5, 1, 2, 4, \<5, 6-10, 11-30, 19, \>30). The plus sign increases with a higher level of occult blood, glucose, ketones, proteins, RBC, WBC in the urine: 1+: slightly positive, 2+: positive, 3+: high positive. Participants were categorized as none seen or 1 based on the absence or presence, respectively, of cast, cellular cast, granular cast and hyaline cast. Higher value indicates higher abnormality.

    Time frame: Baseline (pre-dose Day -1), Day 7 and 15

  6. Summary of Urinalysis Data-mean Specific Gravity

    Data for mean specific gravity is provided. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.

    Time frame: Baseline (pre-dose Day -1), Day 7 and 15

  7. Summary of Urinalysis Data-mean pH

    Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

    Time frame: Baseline (pre-dose Day -1), Day 7 and 15

  8. Number of Participants With Abnormal Electrocardiogram (ECG) Findings Any Time Post-Baseline

    Single 12-lead ECGs was obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Participants with normal, abnormal not clinically significant and abnormal clinically significant ECG is presented.

    Time frame: Up to Day 15

  9. Change From Baseline in Vital Signs Assessments-temperature

    The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.

    Time frame: Baseline (pre-dose Day -1) and, Day 7, 15

  10. Change From Baseline in Vital Signs Assessments-systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.

    Time frame: Baseline (pre-dose Day -1) and Day 7, 15

  11. Change From Baseline in Vital Signs Assessments-heart Rate

    The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.

    Time frame: Baseline (pre-dose Day -1) and Day 7, 15

  12. Number of Bowel Movements (Stool Frequency) as Rated Using the Bristol Stool Form Scale (BSFS) Across Days 1 to 14

    The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.

    Time frame: Up to Day 15 (administered after every in-house bowel movement)

  13. Number of Events With the Rating on Quality of Stools as Rated Using the BSFS Across Days 1 to 14

    The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.

    Time frame: Up to Day 15 (administered after every in-house bowel movement)

  14. Number of Participants With Gastrointestinal Tolerability Assessments as Rated Using the Gastrointestinal Symptom Rating Scale (GSRS; With Worsening Symptoms >=2 Levels)

    GSRS is a rating scale consisting of 15 items. Each item was scored from 1: no discomfort at all, 2: minor discomfort, 3: mild discomfort, 4: moderate discomfort, 5: moderately severe discomfort, 6: severe discomfort, 7: very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 1 to 7; a score of 1 indicates that no symptoms are present, and a score of 7 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity. There were 5 defined syndrome scores and 1 overall score that was derived by computing the mean of the scores for specific subsets of questions as indicated below: abdominal pain (1, 4, 5); reflux syndrome (2, 3); diarrhea syndrome (11, 12, 14); indigestion syndrome (6, 7, 8, 9); constipation syndrome (10, 13, 15) and overall GSRS (1-15). The data is presented for participants with worsening of symptoms in \>=2 levels.

    Time frame: Day 7 and 14

  15. Number of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding

    Testing cards were provided to participants for assessments. Participants with abnormal not clinically significant and abnormal clinically significant is presented. The Day -1 sample was obtained any time starting Day -2 and prior to GSK2330672 dosing on Day 1. The Day 14 sample was collected any time after dosing on Day 14 and prior to discharge on Day 15.

    Time frame: Up to Day 15

Secondary outcomes

  1. PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-maximum Observed Concentration (Cmax)

    The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data. Statistics for geometric least square mean provided.

    Time frame: Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14

  2. PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-time of Occurrence of Cmax (Tmax)

    The time at which Cmax observed was determined directly from the raw concentration-time data.

    Time frame: Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14

  3. PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-area Under the Concentration-time Curve Over the Dosing Interval of 10 Hours (AUC[0-10])

    PK population. Only those participants available at the specified time points were analyzed.

    Time frame: Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14

  4. Ratio to Baseline in Fasting Low-density Cholesterol (LDL) Cholesterol, High-density Cholesterol (HDL) Cholesterol, Total Cholesterol, Non-HDL Cholesterol and Triglycerides

    Data for fasting low-density cholesterol (LDL) cholesterol, high-density cholesterol (HDL) cholesterol, total cholesterol, non-HDL cholesterol and triglycerides is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.

    Time frame: Baseline (pre-dose Day -1) and Day 7, 14

  5. Ratio to Baseline in Fasting Apolipoprotein B

    Data for fasting apolipoprotein B is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.

    Time frame: Baseline (pre-dose Day -1) and Day 7, 14

  6. Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-Cmax Following the First and Second Sitagliptin Doses

    The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Cmax1 and Cmax2).

    Time frame: Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner), 13 and 14 hours (bed time) on Day 14

  7. Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-Tmax Following the First and Second Sitagliptin Doses

    The time at which Cmax was observed by determining directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Tmax1 and Tmax2). If data permits, Tmax2 was defined as the time of Cmax following the second dose of sitagliptin.

    Time frame: Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner), 13 and 14 hours (bed time) on Day 14

  8. Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10)

    The AUC(0-10) following the first dose and prior to the second dose of sitagliptin was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.

    Time frame: Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner) on Day 14

07

Results

Posted Nov 6, 2017

Participant flow

The study was conducted from 27 August 2014 to 30 January 2015. After interim analysis of safety, tolerability, pharmacodynamic and/or pharmacokinetic (PK) data, GSK2330672 10 and 20 milligram (mg) doses were dropped and GSK2330672 60 mg was added.

Participant flow — Overall Study
MilestonePlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BIDRun-in Only
Started13559910136
Completed1245989130
Not completed11001106
Withdrew: Adverse event11000100
Withdrew: Did not meet continuation criteria00000003
Withdrew: Physician decision00000003
Withdrew: Withdrawal by subject00001000

Outcome measures

PrimaryChange From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour])

The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value. It was assessed on Baseline, Day 7 and 14. Data for fasting and weighted mean (WM) AUC(0-24 hour) glucose is provided. Statistics for least square mean is provided and participants withdrawing early were excluded. Results were based on an analysis of covariance (ANCOVA) model: change from Baseline = Baseline + treatment.

Time frame:
Baseline (Day -1) and Day 14 (Fasting Pre-dose [within 15 minutes of dose], 30 minutes, 1, 1.5, 2, 4 [pre-lunch], 5.5, 10 [pre-dinner], 11.5, 14 [bed time] and 24 hours) and Day 7 (30 minutes, 2, 4 [pre-lunch], 5.5, 10 [pre-dinner], 11.5, and 24 hours)
Reported as:
Mean · Mg/deciliter
Change From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour])
Mg/deciliterPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Fasting, Day 7-6.58 ± 16.357-8.25 ± 6.500-1.40 ± 23.050-38.56 ± 24.744-34.38 ± 19.398-24.78 ± 13.414-24.54 ± 33.955
Fasting, Day 14-10.00 ± 19.207-22.75 ± 11.354-16.20 ± 28.709-48.67 ± 32.650-36.13 ± 23.117-40.22 ± 19.156-38.38 ± 16.439
WM AUC(0-24 hour), Day 73.91 ± 20.668-12.14 ± 11.828-7.01 ± 17.262-25.33 ± 25.819-21.47 ± 18.419-14.84 ± 18.569-26.63 ± 23.610
WM AUC(0-24 hour), Day 14-9.94 ± 18.458-22.44 ± 15.928-17.80 ± 16.990-37.48 ± 32.909-32.22 ± 22.948-45.54 ± 21.010-35.85 ± 20.233
Statistical analysis
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): -1.17 · 95% CI -25.61 to 23.27Comparison for fasting, Day 7
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 13.22 · 95% CI -9.84 to 36.27Comparison for fasting, Day 7
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): -21.77 · 95% CI -41.43 to -2.10Comparison for fasting, Day 7
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): -23.10 · 95% CI -42.63 to -3.57Comparison for fasting, Day 7
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -11.79 · 95% CI -30.85 to 7.28Comparison for fasting, Day 7
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): -10.04 · 95% CI -27.66 to 7.57Comparison for fasting, Day 7
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): -15.14 · 95% CI -37.72 to 7.43Comparison for WM AUC(0-24 hour), Day 7
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): -2.10 · 95% CI -23.66 to 19.45Comparison for WM AUC(0-24 hour), Day 7
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): -20.66 · 95% CI -38.75 to -2.57Comparison for WM AUC(0-24 hour), Day 7
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): -21.70 · 95% CI -39.70 to -3.71Comparison for WM AUC(0-24 hour), Day 7
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -10.62 · 95% CI -28.62 to 7.38Comparison for WM AUC(0-24 hour), Day 7
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): -26.03 · 95% CI -41.94 to -10.12Comparison for WM AUC(0-24 hour), Day 7
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): -12.10 · 95% CI -33.56 to 9.36Comparison for fasting, Day 14
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 4.33 · 95% CI -15.91 to 24.57Comparison for fasting, Day 14
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): -25.29 · 95% CI -42.56 to -8.02Comparison for fasting, Day 14
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): -19.97 · 95% CI -37.12 to -2.82Comparison for fasting, Day 14
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -21.82 · 95% CI -38.56 to -5.08Comparison for fasting, Day 14
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): -18.01 · 95% CI -33.48 to -2.55Comparison for fasting, Day 14
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): -11.20 · 95% CI -33.21 to 10.81Comparison for WM AUC(0-24 hour), Day 14
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 4.80 · 95% CI -16.22 to 25.81Comparison for WM AUC(0-24 hour), Day 14
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): -15.23 · 95% CI -32.86 to 2.41Comparison for WM AUC(0-24 hour), Day 14
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): -17.01 · 95% CI -34.56 to 0.53Comparison for WM AUC(0-24 hour), Day 14
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -23.94 · 95% CI -41.49 to -6.39Comparison for WM AUC(0-24 hour), Day 14
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): -19.45 · 95% CI -34.96 to -3.93Comparison for WM AUC(0-24 hour), Day 14
PrimaryNumber of Participants With Incidence and Nature of Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition and alanine aminotransferase (ALT) \>= 3× upper limit of normal (ULN) and total bilirubin \>=2 × ULN (\>35% direct) or ALT \>=3 × ULN and international normalized ratio \>1.5.

Time frame:
Up to 14 days (treatment period)
Reported as:
Count of participants · Participants
Number of Participants With Incidence and Nature of Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Any AE9455888
Any SAE0100000
PrimaryNumber of Participants With Abnormal Hematology With Potential Clinical Concern (PCI)

Hematology parameters included platelet, red blood cell (RBC) count, mean corpuscular volume (MCV), neutrophils, white blood cell (WBC) count (absolute), mean corpuscular hemoglobin (MCH), lymphocytes, mean corpuscular hemoglobin concentration (MCHC), monocytes, hemoglobin, eosinophils, hematocrit and basophils. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided.

Time frame:
Up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hematology With Potential Clinical Concern (PCI)
ParticipantsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Number of Participants With Abnormal Hematology With Potential Clinical Concern (PCI)0000010
PrimaryNumber of Participants With Abnormal Clinical Chemistry With PCI

Clinical chemistry parameters included blood urea nitrogen (BUN), potassium, aspartate aminotransferase (AST), total bilirubin, direct bilirubin, creatinine, chloride, alanine aminotransferase (ALT), uric acid, fasting glucose, total carbon dioxide, gamma glutamyltransferase (GGT), albumin, sodium, calcium, alkaline phosphatase (ALP), total protein, total carbon dioxide and triglycerides. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Data for parameters with above and below the PCI is provided. The normal range (NR) and PCI definition for abnormal parameters are: ALT (NR: 0-44, 0-32, 2-33; PCI: \>=2×upper limit of normal \[ULN\]); AST (NR: 0-40; PCI: \>=2× ULN) and total bilirubin (NR: 0.00-20.52; PCI: \>=1.5× ULN).

Time frame:
Up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Chemistry With PCI
ParticipantsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
ALT, high1022211
AST, high0000100
Total Bilirubin, hgh0000100
PrimaryNumber of Participants With Abnormal Urinalysis Data

Urinalysis included urine occult blood: trace to 3+, glucose: negative to 3+, protein: negative to 2+ and ketones: trace to negative by dipstick and microscopic examination included cast, cellular cast, granular cast, hyaline cast (none seen to 1) and RBC: 0-2, 3-10, 11-30, \>30, WBC: none seen, 0-5, 1, 2, 4, \<5, 6-10, 11-30, 19, \>30). The plus sign increases with a higher level of occult blood, glucose, ketones, proteins, RBC, WBC in the urine: 1+: slightly positive, 2+: positive, 3+: high positive. Participants were categorized as none seen or 1 based on the absence or presence, respectively, of cast, cellular cast, granular cast and hyaline cast. Higher value indicates higher abnormality.

Time frame:
Baseline (pre-dose Day -1), Day 7 and 15
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Data
ParticipantsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Urine Occult Blood, Day -1, Trace0100001
Urine Occult Blood, Day -1, small0000100
Urine Occult Blood, Day-1, 3+0100000
Urine Occult Blood, Day 7, Trace0110001
Urine Occult Blood, Day 7, Trace intact0000001
Urine Occult Blood, Day 7, small0000100
Urine Occult Blood, Day 7, 1+0000001
Urine Occult Blood, Day 15, Trace0000001
Urine Occult Blood, Day 15, small0000100
Urine Occult Blood, Day 15, 2+1000000
Urine Microscopy-Casts, Day 7, none seen0000001
Urine Microscopy-Cellular Casts, Day -1, none seen0000101
Urine Microscopy-Cellular Casts, Day 7, none seen0000201
Urine Microscopy-Cellular Casts, Day 15, none seen0000201
Urine Microscopy-Granular Casts, Day -1, none seen0000101
Urine Microscopy-Granular Casts, Day 7, none seen0000201
Urine Microscopy-Granular Casts, Day 15, none seen0000201
Urine Glucose, Day -1, Trace1011120
Urine Glucose, Day -1, 1+0003000
Urine Glucose, Day -1, 2+0000100
Urine Glucose, Day -1, 3+0000102
Urine Glucose, Day 7, Trace0002111
Urine Glucose, Day 7, 1+1010001
Urine Microscopy-Hyaline Casts, Day -1, none seen0000101
Urine Microscopy-Hyaline Casts, Day 7, None seen0000101
Urine Microscopy-Hyaline Casts, Day 7, 10000100
Urine Microscopy-Hyaline Casts, Day 15, none seen0000201
Urine Ketones, Day 7, Trace0010000
Urine Protein, Day -1, 1+0001000
Urine Protein, Day 7, 2+0001000
Urine Protein, Day 15, Trace1000010
Urine Protein, Day 15, 1+0001000
Urine Microscopy-RBC, Day -1, none seen2001001
Urine Microscopy-RBC, Day -1, 0-21000001
Urine Microscopy-RBC, Day -1, 3-100110001
Urine Microscopy-RBC, Day -1, 11-300100000
Urine Microscopy-RBC, Day 7, none seen1100002
Urine Microscopy-RBC, Day 7, 0-20010010
Urine Microscopy-RBC, Day 15, none seen0001001
Urine Microscopy-RBC, Day 7, 3-100000001
Urine Microscopy-WBC, Day -1, none seen2201001
Urine Microscopy-WBC, Day -1, 0-51000000
Urine Microscopy-WBC, Day -1, 10000100
Urine Microscopy-WBC, Day -1, 40000001
Urine Microscopy-WBC, Day -1, 6-100010000
Urine Microscopy-WBC, Day -1, 11-300000001
Urine Microscopy-WBC, Day -1, >300000001
Urine Microscopy-WBC, Day 7, 0-51110000
Urine Microscopy-WBC, Day 7, 10000200
Urine Microscopy-WBC, Day 7, <50000001
Urine Microscopy-WBC, Day 7, 11-300000011
Urine Microscopy-WBC, Day 7, 190000001
Urine Microscopy-WBC, Day 7, >300000001
Urine Microscopy-WBC, Day 15, 0-51011000
Urine Microscopy-WBC, Day 15, 10000001
Urine Microscopy-WBC, Day 15, 20000100
Urine Microscopy-WBC, Day 15, 40000100
Urine Microscopy-WBC, Day 15, 11-300000001
Urine Microscopy-WBC, Day 15, >300000001
PrimarySummary of Urinalysis Data-mean Specific Gravity

Data for mean specific gravity is provided. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.

Time frame:
Baseline (pre-dose Day -1), Day 7 and 15
Reported as:
Mean · Ratio
Summary of Urinalysis Data-mean Specific Gravity
RatioPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Day -11.0193 ± 0.006941.0182 ± 0.005811.0128 ± 0.004211.0190 ± 0.006181.0172 ± 0.006101.0189 ± 0.007801.0148 ± 0.00706
Day 71.0196 ± 0.007531.0208 ± 0.009041.0184 ± 0.008961.0191 ± 0.007391.0194 ± 0.007261.0208 ± 0.008591.0160 ± 0.00790
Day 151.0188 ± 0.004031.0193 ± 0.004351.0158 ± 0.002591.0132 ± 0.004711.0121 ± 0.003481.0160 ± 0.007871.0140 ± 0.00815
PrimarySummary of Urinalysis Data-mean pH

Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Time frame:
Baseline (pre-dose Day -1), Day 7 and 15
Reported as:
Mean · Unit on a scale
Summary of Urinalysis Data-mean pH
Unit on a scalePlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Day -15.73 ± 0.3886.00 ± 0.0006.10 ± 0.2246.11 ± 0.2205.83 ± 0.3545.95 ± 0.4385.85 ± 0.516
Day 75.83 ± 0.3895.90 ± 0.2246.00 ± 0.0005.89 ± 0.2205.61 ± 0.4865.95 ± 0.2845.69 ± 0.435
Day 155.88 ± 0.3775.88 ± 0.2506.00 ± 0.0006.00 ± 0.0005.72 ± 0.5656.06 ± 0.1675.88 ± 0.416
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings Any Time Post-Baseline

Single 12-lead ECGs was obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. It was assessed on Baseline (pre-dose Day -1), Day 7 and 15. Participants with normal, abnormal not clinically significant and abnormal clinically significant ECG is presented.

Time frame:
Up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Any Time Post-Baseline
ParticipantsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Normal9448669
Abnormal not clinically significant4011344
Abnormal clinically significant0100000
PrimaryChange From Baseline in Vital Signs Assessments-temperature

The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.

Time frame:
Baseline (pre-dose Day -1) and, Day 7, 15
Reported as:
Mean · Degree Celsius
Change From Baseline in Vital Signs Assessments-temperature
Degree CelsiusPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Day 7-0.133 ± 0.2570-0.280 ± 0.47640.040 ± 0.43930.033 ± 0.39370.033 ± 0.20620.010 ± 0.44580.015 ± 0.4451
Day 15-0.208 ± 0.33700.025 ± 0.1708-0.040 ± 0.2966-0.111 ± 0.56220.056 ± 0.2744-0.178 ± 0.59950.062 ± 0.3404
PrimaryChange From Baseline in Vital Signs Assessments-systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.

Time frame:
Baseline (pre-dose Day -1) and Day 7, 15
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Vital Signs Assessments-systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
DBP, Day 7-0.083 ± 6.8152-1.600 ± 8.5323-6.600 ± 1.9494-1.556 ± 10.7948-4.111 ± 4.9861-2.700 ± 6.7007-2.462 ± 7.6770
DBP, Day 150.750 ± 6.1070-2.750 ± 4.57351.800 ± 5.8481-1.333 ± 9.1104-1.667 ± 3.9370-2.667 ± 6.3048-0.769 ± 5.0852
SBP, Day 72.250 ± 8.4544-4.000 ± 10.2225-15.600 ± 6.14822.222 ± 17.69731.222 ± 9.1211-4.300 ± 10.9245-5.462 ± 10.3571
SBP, Day 152.167 ± 8.5049-4.500 ± 10.47220.600 ± 11.8870-5.111 ± 11.9105-1.000 ± 9.3541-2.111 ± 9.5321-4.385 ± 9.2334
PrimaryChange From Baseline in Vital Signs Assessments-heart Rate

The change from Baseline was calculated by subtracting the Baseline values from the individual post-Baseline values. Baseline was defined as pre-dose Day -1 value.

Time frame:
Baseline (pre-dose Day -1) and Day 7, 15
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Signs Assessments-heart Rate
Beats per minutePlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Day 7-0.500 ± 8.12969.200 ± 8.22804.400 ± 7.40270.556 ± 5.29414.667 ± 4.06201.400 ± 7.0269-0.769 ± 6.2471
Day 150.083 ± 3.11760.250 ± 6.34439.200 ± 3.1937-0.444 ± 8.29324.889 ± 7.42370.000 ± 8.80341.846 ± 9.1364
PrimaryNumber of Bowel Movements (Stool Frequency) as Rated Using the Bristol Stool Form Scale (BSFS) Across Days 1 to 14

The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.

Time frame:
Up to Day 15 (administered after every in-house bowel movement)
Reported as:
Mean · Count of bowel movements
Number of Bowel Movements (Stool Frequency) as Rated Using the Bristol Stool Form Scale (BSFS) Across Days 1 to 14
Count of bowel movementsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BIDRun-in Only
Number of Bowel Movements (Stool Frequency) as Rated Using the Bristol Stool Form Scale (BSFS) Across Days 1 to 1415.2 ± 9.2928.2 ± 17.4738.4 ± 10.7435.0 ± 18.4937.3 ± 30.7235.9 ± 21.6715.0 ± 10.96—
PrimaryNumber of Events With the Rating on Quality of Stools as Rated Using the BSFS Across Days 1 to 14

The site staff classified participant's stools and record the date and time of occurrence after any bowel movement that occurs while participants were in residence in the clinic. BSFS is scale between type 1-7, it measured the shape of the stool, type 1: separate hard lumps, like nuts; type 2: sausage shaped but lumpy; type 3: like a sausage or snake but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges; type 6: fluffy pieces with ragged edges, a mushy stool and type 7: watery, no solid pieces. Participants were discharged after they have had at least one bowel movement after the Day 14 dosing and after the investigator/designee had reviewed the Day 15 end of study questions.

Time frame:
Up to Day 15 (administered after every in-house bowel movement)
Reported as:
Number · Events
Number of Events With the Rating on Quality of Stools as Rated Using the BSFS Across Days 1 to 14
EventsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
BSFS scale rating, 1 event : Events2——1—12
BSFS scale rating, 2 events : Events6—21——10
BSFS scale rating, 3 events : Events28—416536
BSFS scale rating, 4 events : Events5671819212441
BSFS scale rating, 5 events : Events30282693026
BSFS scale rating, 6 events : Events598111318125020170
BSFS scale rating, 7 events : Events16514786509810
PrimaryNumber of Participants With Gastrointestinal Tolerability Assessments as Rated Using the Gastrointestinal Symptom Rating Scale (GSRS; With Worsening Symptoms >=2 Levels)

GSRS is a rating scale consisting of 15 items. Each item was scored from 1: no discomfort at all, 2: minor discomfort, 3: mild discomfort, 4: moderate discomfort, 5: moderately severe discomfort, 6: severe discomfort, 7: very severe discomfort. The overall GSRS score is the mean of these 15 items, varying from 1 to 7; a score of 1 indicates that no symptoms are present, and a score of 7 indicates the worst possible degree of all symptoms. A higher score relative to Baseline indicates worsening of severity. There were 5 defined syndrome scores and 1 overall score that was derived by computing the mean of the scores for specific subsets of questions as indicated below: abdominal pain (1, 4, 5); reflux syndrome (2, 3); diarrhea syndrome (11, 12, 14); indigestion syndrome (6, 7, 8, 9); constipation syndrome (10, 13, 15) and overall GSRS (1-15). The data is presented for participants with worsening of symptoms in \>=2 levels.

Time frame:
Day 7 and 14
Reported as:
Count of participants · Participants
Number of Participants With Gastrointestinal Tolerability Assessments as Rated Using the Gastrointestinal Symptom Rating Scale (GSRS; With Worsening Symptoms >=2 Levels)
ParticipantsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Pain/discomfort in upper abdomen, Day 70022000
Heartburn, Day 70010010
Acid reflux, Day 70010010
Hunger pains, Day 70010110
Nausea, Day 71000001
Rumbling, Day 71020120
Bloated, Day 72011030
Burping, Day 71010020
Passing gas or flatus, Day 71111020
Constipation, Day 71034300
Diarrhea, Day 70023440
Loose stools, Day 71034330
Hard stools, Day 70000010
Urgent need to have bowel movement, Day 71021220
Sensatn not complete empty bowels, Day 70022320
Abdominal pain, Day 70010000
Reflux syndrome, Day 70010010
Indigestion syndrome, Day 71010020
Constipation syndrome, Day 70000000
Diarrhea syndrome, Day 70023220
Overall GSRS, Day 70010010
Pain/discomfort in upper abdomen, Day 141121111
Heartburn, Day 141020000
Acid reflux, Day 141110010
Hunger pains, Day 140022020
Nausea, Day 140010000
Rumbling, Day 141121020
Bloated, Day 1421210300
Burping, Day 141110020
Passing gas or flatus, Day 140122020
Constipation, Day 140110020
Diarrhea, Day 141043250
Loose stools, Day 141132330
Hard stools, Day 140020010
Urgent need to have bowel movement, Day 141142330
Sensation not complete empty bowels, Day 140032320
Abdominal pain, Day 140010000
Reflux syndrome, Day 141010010
Indigestion syndrome, Day 140111020
Constipation syndrome, Day 140020020
Diarrhea syndrome, Day 140032130
Overall GSRS, Day 140011020
PrimaryNumber of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding

Testing cards were provided to participants for assessments. Participants with abnormal not clinically significant and abnormal clinically significant is presented. The Day -1 sample was obtained any time starting Day -2 and prior to GSK2330672 dosing on Day 1. The Day 14 sample was collected any time after dosing on Day 14 and prior to discharge on Day 15.

Time frame:
Up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding
ParticipantsPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BIDRun-in Only
Abnormal not clinically significant01100110
Abnormal clinically significant00000102
SecondaryPK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-maximum Observed Concentration (Cmax)

The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data. Statistics for geometric least square mean provided.

Time frame:
Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14
Reported as:
Geometric least squares mean · Nanograms per milliliter (ng/mL)
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-maximum Observed Concentration (Cmax)
Nanograms per milliliter (ng/mL)PlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-maximum Observed Concentration (Cmax)1102.2 ± 26.921289.3 ± 41.811219.9 ± 23.761160.0 ± 18.641378.8 ± 22.771376.6 ± 21.701223.5 ± 27.36
Statistical analysis
  • Placebo vs GSK2330672 10 mg BID · Ratio: 1.17 · 90% CI 0.92 to 1.49Mean and confidence interval (CI) for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 20 mg BID · Ratio: 1.11 · 90% CI 0.89 to 1.38Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 30 mg BID · Ratio: 1.05 · 90% CI 0.87 to 1.27Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 60 mg BID · Ratio: 1.25 · 90% CI 1.03 to 1.52Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 90 mg BID · Ratio: 1.25 · 90% CI 1.04 to 1.50Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs Sitagliptin 50 mg BID · Ratio: 1.11 · 90% CI 0.94 to 1.31Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
SecondaryPK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-time of Occurrence of Cmax (Tmax)

The time at which Cmax observed was determined directly from the raw concentration-time data.

Time frame:
Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14
Reported as:
Median · Hour
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-time of Occurrence of Cmax (Tmax)
HourPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-time of Occurrence of Cmax (Tmax)1.510 (1.00 to 4.00)1.000 (1.00 to 1.50)1.000 (0.50 to 3.98)1.050 (1.00 to 1.50)1.750 (0.50 to 4.00)1.500 (1.00 to 4.00)2.050 (1.00 to 4.02)
SecondaryPK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-area Under the Concentration-time Curve Over the Dosing Interval of 10 Hours (AUC[0-10])

PK population. Only those participants available at the specified time points were analyzed.

Time frame:
Fasting pre-dose (within 15 minutes of dose), 30 minutes, 1, 1.5, 2, 3, 4 (pre-lunch), 5.5, 8, 10 hours (pre-dinner) on Day 14
Reported as:
Geometric mean · Hour×ng/mL
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-area Under the Concentration-time Curve Over the Dosing Interval of 10 Hours (AUC[0-10])
Hour×ng/mLPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
PK Parameters for Metformin Steady State PK Parameters When Co-dosed With GSK2330672, Sitagliptin or Placebo-area Under the Concentration-time Curve Over the Dosing Interval of 10 Hours (AUC[0-10])6805.8 ± 19.705982.0 ± 34.727066.2 ± 25.807066.5 ± 16.098090.5 ± 33.068375.3 ± 32.788425.4 ± 28.11
Statistical analysis
  • Placebo vs GSK2330672 10 mg BID · Ratio: 0.88 · 90% CI 0.68 to 1.13Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 20 mg BID · Ratio: 1.04 · 90% CI 0.82 to 1.31Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 30 mg BID · Ratio: 1.04 · 90% CI 0.85 to 1.26Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 60 mg BID · Ratio: 1.19 · 90% CI 0.97 to 1.45Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs GSK2330672 90 mg BID · Ratio: 1.23 · 90% CI 1.01 to 1.49Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
  • Placebo vs Sitagliptin 50 mg BID · Ratio: 1.24 · 90% CI 1.04 to 1.48Mean and CI for the difference in least squares means (Active-Placebo) are back-transformed to form the point estimate and associated CI for the ratio of geometric means.
SecondaryRatio to Baseline in Fasting Low-density Cholesterol (LDL) Cholesterol, High-density Cholesterol (HDL) Cholesterol, Total Cholesterol, Non-HDL Cholesterol and Triglycerides

Data for fasting low-density cholesterol (LDL) cholesterol, high-density cholesterol (HDL) cholesterol, total cholesterol, non-HDL cholesterol and triglycerides is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.

Time frame:
Baseline (pre-dose Day -1) and Day 7, 14
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Fasting Low-density Cholesterol (LDL) Cholesterol, High-density Cholesterol (HDL) Cholesterol, Total Cholesterol, Non-HDL Cholesterol and Triglycerides
RatioPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Cholesterol, Day 70.95 ± 10.90.99 ± 12.10.84 ± 12.40.84 ± 13.70.74 ± 11.00.80 ± 3.70.97 ± 9.8
Cholesterol, Day 140.95 ± 13.10.98 ± 14.20.81 ± 20.80.83 ± 18.50.75 ± 8.80.75 ± 6.70.92 ± 11.1
HDL cholesterol, Day 71.00 ± 7.31.08 ± 12.81.05 ± 8.90.97 ± 8.00.95 ± 11.41.09 ± 15.70.97 ± 9.0
HDL cholesterol, Day 140.99 ± 6.51.11 ± 1.51.02 ± 4.00.97 ± 8.80.96 ± 11.41.01 ± 11.60.97 ± 10.2
LDL cholesterol, Day 70.97 ± 14.60.89 ± 6.40.77 ± 21.10.73 ± 21.50.58 ± 21.20.71 ± 6.51.00 ± 10.5
LDL cholesterol, Day 140.94 ± 17.60.80 ± 4.20.69 ± 23.10.72 ± 23.70.60 ± 15.00.67 ± 16.30.92 ± 15.3
Non-HDL Cholesterol, Day 70.93 ± 13.80.96 ± 12.60.78 ± 18.20.80 ± 18.20.65 ± 12.00.73 ± 5.10.98 ± 11.9
Non-HDL Cholesterol, Day 140.94 ± 17.70.94 ± 17.50.74 ± 29.70.78 ± 23.70.67 ± 7.20.68 ± 8.60.90 ± 15.1
Triglycerides, Day 70.85 ± 20.61.07 ± 51.20.93 ± 18.81.11 ± 24.50.98 ± 19.80.93 ± 16.30.79 ± 32.7
Triglycerides, Day 140.85 ± 23.01.21 ± 63.30.96 ± 35.81.07 ± 34.31.00 ± 16.61.00 ± 23.70.74 ± 34.5
Statistical analysis
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 1.03 · 95% CI 0.91 to 1.17Comparison for Day 7, cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.88 · 95% CI 0.78 to 0.98Comparison for Day 7, cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.86 · 95% CI 0.78 to 0.95Comparison for Day 7, cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.75 · 95% CI 0.68 to 0.83Comparison for Day 7, cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.83 · 95% CI 0.76 to 0.92Comparison for Day 7, cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 1.01 · 95% CI 0.92 to 1.10Comparison for Day 7, cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 1.07 · 95% CI 0.95 to 1.19Comparison for Day 7, HDL cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 1.04 · 95% CI 0.94 to 1.16Comparison for Day 7, HDL cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.96 · 95% CI 0.88 to 1.05Comparison for Day 7, HDL cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.98 · 95% CI 0.89 to 1.07Comparison for Day 7, HDL cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 1.07 · 95% CI 0.98 to 1.17Comparison for Day 7, HDL cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.97 · 95% CI 0.90 to 1.05Comparison for Day 7, HDL cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 0.95 · 95% CI 0.80 to 1.13Comparison for Day 7, LDL cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.76 · 95% CI 0.65 to 0.90Comparison for Day 7, LDL cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.74 · 95% CI 0.64 to 0.85Comparison for Day 7, LDL cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.59 · 95% CI 0.51 to 0.69Comparison for Day 7, LDL cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.71 · 95% CI 0.62 to 0.81Comparison for Day 7, LDL cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 1.00 · 95% CI 0.89 to 1.14Comparison for Day 7, LDL cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 1.03 · 95% CI 0.88 to 1.21Comparison for Day 7, non-HDL cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.82 · 95% CI 0.71 to 0.95Comparison for Day 7, non-HDL cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.84 · 95% CI 0.74 to 0.95Comparison for Day 7, non-HDL cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.67 · 95% CI 0.59 to 0.76Comparison for Day 7, non-HDL cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.77 · 95% CI 0.68 to 0.87Comparison for Day 7, non-HDL cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 1.02 · 95% CI 0.92 to 1.14Comparison for Day 7, non-HDL cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 1.27 · 95% CI 0.97 to 1.66Comparison for Day 7, triglycerides
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 1.16 · 95% CI 0.90 to 1.50Comparison for Day 7, triglycerides
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 1.30 · 95% CI 1.06 to 1.61Comparison for Day 7, triglycerides
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 1.19 · 95% CI 0.96 to 1.48Comparison for Day 7, triglycerides
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 1.15 · 95% CI 0.93 to 1.42Comparison for Day 7, triglycerides
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.95 · 95% CI 0.79 to 1.16Comparison for Day 7, triglycerides
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 1.00 · 95% CI 0.86 to 1.17Comparison for Day 14, cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.83 · 95% CI 0.73 to 0.96Comparison for Day 14, cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.82 · 95% CI 0.73 to 0.91Comparison for Day 14, cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.74 · 95% CI 0.66 to 0.82Comparison for Day 14, cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.77 · 95% CI 0.69 to 0.86Comparison for Day 14, cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.93 · 95% CI 0.84 to 1.03Comparison for Day 14, cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 1.09 · 95% CI 0.99 to 1.21Comparison for Day 14, HDL cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 1.02 · 95% CI 0.93 to 1.11Comparison for Day 14, HDL cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.97 · 95% CI 0.90 to 1.04Comparison for Day 14, HDL cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.99 · 95% CI 0.92 to 1.06Comparison for Day 14, HDL cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 1.01 · 95% CI 0.94 to 1.08Comparison for Day 14, HDL cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.98 · 95% CI 0.92 to 1.04Comparison for Day 14, HDL cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 0.85 · 95% CI 0.69 to 1.04Comparison for Day 14, LDL cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.70 · 95% CI 0.58 to 0.85Comparison for Day 14, LDL cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.73 · 95% CI 0.62 to 0.86Comparison for Day 14, LDL cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.60 · 95% CI 0.50 to 0.71Comparison for Day 14, LDL cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.69 · 95% CI 0.59 to 0.80Comparison for Day 14, LDL cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.94 · 95% CI 0.81 to 1.09Comparison for Day 14, LDL cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 0.99 · 95% CI 0.80 to 1.22Comparison for Day 14, non-HDL cholesterol
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.77 · 95% CI 0.64 to 0.93Comparison for Day 14, non-HDL cholesterol
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.77 · 95% CI 0.67 to 0.90Comparison for Day 14, non-HDL cholesterol
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.65 · 95% CI 0.55 to 0.75Comparison for Day 14, non-HDL cholesterol
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.70 · 95% CI 0.60 to 0.81Comparison for Day 14, non-HDL cholesterol
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.91 · 95% CI 0.80 to 1.04Comparison for Day 14, non-HDL cholesterol
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 1.42 · 95% CI 1.01 to 2.00Comparison for Day 14, triglycerides
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 1.28 · 95% CI 0.94 to 1.75Comparison for Day 14, triglycerides
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 1.24 · 95% CI 0.98 to 1.58Comparison for Day 14, triglycerides
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 1.22 · 95% CI 0.95 to 1.56Comparison for Day 14, triglycerides
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 1.23 · 95% CI 0.96 to 1.57Comparison for Day 14, triglycerides
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.89 · 95% CI 0.72 to 1.11Comparison for Day 14, triglycerides
SecondaryRatio to Baseline in Fasting Apolipoprotein B

Data for fasting apolipoprotein B is presented. Participants withdrawing early were excluded. Results were based on an ANCOVA model: Log(post-Baseline) - Log(Baseline) = Log(Baseline) + treatment + concomitant use of lipid lowering drugs.

Time frame:
Baseline (pre-dose Day -1) and Day 7, 14
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Fasting Apolipoprotein B
RatioPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Day 70.97 ± 10.60.95 ± 5.90.78 ± 13.90.81 ± 13.10.69 ± 12.00.76 ± 3.80.96 ± 10.3
Day 140.93 ± 14.20.85 ± 6.70.75 ± 19.00.78 ± 19.60.67 ± 14.90.69 ± 9.30.88 ± 15.5
Statistical analysis
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 0.98 · 95% CI 0.87 to 1.11Comparison for Day 7, apolipoprotein B
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.79 · 95% CI 0.71 to 0.89Comparison for Day 7, apolipoprotein B
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.82 · 95% CI 0.74 to 0.90Comparison for Day 7, apolipoprotein B
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.70 · 95% CI 0.63 to 0.77Comparison for Day 7, apolipoprotein B
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.77 · 95% CI 0.70 to 0.85Comparison for Day 7, apolipoprotein B
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.97 · 95% CI 0.89 to 1.06Comparison for Day 7, apolipoprotein B
  • Placebo vs GSK2330672 10 mg BID · Mean difference (net): 0.91 · 95% CI 0.77 to 1.07Comparison for Day 14, apolipoprotein B
  • Placebo vs GSK2330672 20 mg BID · Mean difference (net): 0.81 · 95% CI 0.68 to 0.95Comparison for Day 14, apolipoprotein B
  • Placebo vs GSK2330672 30 mg BID · Mean difference (net): 0.80 · 95% CI 0.70 to 0.91Comparison for Day 14, apolipoprotein B
  • Placebo vs GSK2330672 60 mg BID · Mean difference (net): 0.67 · 95% CI 0.58 to 0.77Comparison for Day 14, apolipoprotein B
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.73 · 95% CI 0.64 to 0.83Comparison for Day 14, apolipoprotein B
  • Placebo vs Sitagliptin 50 mg BID · Mean difference (net): 0.90 · 95% CI 0.80 to 1.02Comparison for Day 14, apolipoprotein B
SecondarySitagliptin Steady State PK Parameters When Co-dosed With Metformin-Cmax Following the First and Second Sitagliptin Doses

The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Cmax1 and Cmax2).

Time frame:
Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner), 13 and 14 hours (bed time) on Day 14
Reported as:
Geometric mean · Ng/mL
Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-Cmax Following the First and Second Sitagliptin Doses
Ng/mLSitagliptin 50 mg BID
Cmax 1238.2 ± 26.20
Cmax 2188.5 ± 25.34
SecondarySitagliptin Steady State PK Parameters When Co-dosed With Metformin-Tmax Following the First and Second Sitagliptin Doses

The time at which Cmax was observed by determining directly from the raw concentration-time data following the first and second dose of sitagliptin on Day 14 (Tmax1 and Tmax2). If data permits, Tmax2 was defined as the time of Cmax following the second dose of sitagliptin.

Time frame:
Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner), 13 and 14 hours (bed time) on Day 14
Reported as:
Median · Hour
Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-Tmax Following the First and Second Sitagliptin Doses
HourSitagliptin 50 mg BID
Tmax 12.000 (1.00 to 3.98)
Tmax 23.050 (2.98 to 4.07)
SecondarySitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10)

The AUC(0-10) following the first dose and prior to the second dose of sitagliptin was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.

Time frame:
Fasting pre-dose (within 15 minutes of dose), 1, 2, 3, 4 (pre-lunch), 10 (pre-dinner) on Day 14
Reported as:
Geometric mean · Hour×ng/mL
Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10)
Hour×ng/mLSitagliptin 50 mg BID
Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10)1473.5 ± 22.45

Adverse events

Collected over AEs and SAEs were collected from run-in period until the follow-up contact (7-10 days after discharge). SAEs and non-SAE were reported from treatment period only (up to 14 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/13 (0%)0/13 (0%)9/13 (69.2%)
GSK2330672 10 mg BID0/5 (0%)1/5 (20%)3/5 (60%)
GSK2330672 20 mg BID0/5 (0%)0/5 (0%)5/5 (100%)
GSK2330672 30 mg BID0/9 (0%)0/9 (0%)5/9 (55.6%)
GSK2330672 60 mg BID0/9 (0%)0/9 (0%)8/9 (88.9%)
GSK2330672 90 mg BID0/10 (0%)0/10 (0%)8/10 (80%)
Sitagliptin 50 mg BID0/13 (0%)0/13 (0%)8/13 (61.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
Arrhythmia supraventricularCardiac disorders0/131/50/50/90/90/100/13
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BID
DiarrhoeaGastrointestinal disorders4/132/55/52/97/96/102/13
Abdominal painGastrointestinal disorders2/131/52/52/91/92/101/13
FlatulenceGastrointestinal disorders1/130/51/50/91/93/101/13
Faeces softGastrointestinal disorders1/130/50/52/91/92/100/13
NauseaGastrointestinal disorders1/130/50/50/92/90/101/13
HeadacheNervous system disorders2/130/50/50/92/91/100/13
Viral infectionInfections and infestations0/130/50/50/92/90/100/13
DyspepsiaGastrointestinal disorders0/131/51/50/90/90/102/13
ProctalgiaGastrointestinal disorders0/131/50/50/91/91/100/13
EructationGastrointestinal disorders1/131/50/50/90/90/100/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BIDRun-in OnlyTotal
Mean52.1 ± 6.9754.0 ± 4.3056.2 ± 8.5057.1 ± 5.8655.0 ± 4.2754.8 ± 7.4753.7 ± 6.7955.5 ± 3.5154.5 ± 6.20
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BIDRun-in OnlyTotal
Female4342645331
Male9217368339
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGSK2330672 10 mg BIDGSK2330672 20 mg BIDGSK2330672 30 mg BIDGSK2330672 60 mg BIDGSK2330672 90 mg BIDSitagliptin 50 mg BIDRun-in OnlyTotal
American Indian or Alaska Native000000000
Asian000001001
Native Hawaiian or Other Pacific Islander001020003
Black or African American3101303112
White104484910554
More than one race000000000
Unknown or Not Reported000000000
08

Study locations

4 sites
  • GSK Investigational Site
    Chula Vista, California 91910, United States
  • GSK Investigational Site
    Miami, Florida 33169, United States
  • GSK Investigational Site
    Baltimore, Maryland 21225, United States
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Jan 2015, 5 months.

Results were first posted in Nov 2017, 2 years 9 months after primary completion. A results delay was requested in May 2015.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 5 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2014
First posted
Jul 28, 2014
StartActual
Aug 27, 2014
Primary completionActual
Jan 30, 2015
CompletionActual
Jan 30, 2015
Results delay requested
May 14, 2015
Results first posted
Nov 6, 2017
Last update
Nov 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02202161
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 28, 2014
Start date
Aug 27, 2014
Primary completion
Jan 30, 2015
Completion
Jan 30, 2015
Results posted
Nov 6, 2017
Last update
Nov 6, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linerixibat

Start the discussion